February 2026
PTSD
What February 2026's 7 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research in February 2026 indicates that MDMA-assisted therapy shows promise for PTSD, with evidence of durable symptom remission and a proposed dual-action mechanism involving both neurobiological and relational factors. Real-world data on at-home ketamine-assisted therapy also suggests large reductions in PTSD symptoms, though this evidence comes from an uncontrolled retrospective analysis. A key caveat is that much of the evidence remains preliminary, with limited long-term follow-up and a need for more rigorous controlled trials.
Confidence in the evidence
Low-Moderate- The evidence includes a mix of reviews, a meta-analytic dataset, a retrospective analysis, and qualitative studies, but lacks large-scale randomized controlled trials published in this period.
- The retrospective analysis on ketamine (n=374) shows large effect sizes but is uncontrolled and from a single telehealth platform, limiting generalizability.
- Qualitative studies (n=6 and n=21) provide valuable insights but are small and not designed to establish efficacy.
- The reviews and meta-analytic dataset are consistent in suggesting positive effects for MDMA, but the evidence base is still developing.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment 2026 | review | Supports | This position paper discusses SSRIs, psilocybin, and MDMA as therapeutic modalities for PTSD, emphasizing the need for better understanding of their neurobiological mechanisms and intellectual property considerations. | |
| metapsy-project/data-ptsd-mdmactr: Version 26.0.0 2026 | meta-analytic dataset | Supports | This living meta-analytic dataset includes MDMA therapy vs. control comparisons for PTSD, providing effect sizes at post-test and long-term follow-ups, with data independently extracted and risk of bias assessed. | |
| MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst? 2026 | review | Supports | This review proposes a synergistic model where MDMA-assisted therapy works through both neurobiological mechanisms (fear extinction, neuroplasticity) and relational mechanisms (enhanced therapeutic alliance), creating a 'window of emotional safety'. | |
| At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis 2026 | retrospective analysis | 374 | Supports | At-home ketamine-assisted therapy was associated with a 44.6% reduction in PTSD symptoms (Cohen's d=1.44), with 79.7% clinical response and 60.7% remission rates after six sessions. |
| Lifetime MDMA use and associations with meaning in life in the context of childhood trauma 2026 | observational | 807 | Mixed | Lifetime MDMA use was not significantly associated with meaning in life overall, but a significant interaction showed that MDMA use was associated with higher meaning in life among individuals with a history of childhood trauma. |
| Barriers and Access to Care for Firefighters with Post-Traumatic Stress Disorder Seeking Ketamine Assisted Therapy: a qualitative study. 2026 | qualitative | 6 | Unclear | Firefighters reported feeling stuck, stigma around PTSD and ketamine, the need for self-advocacy, and substantial financial/logistical barriers to accessing ketamine-assisted therapy. |
| Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis. 2026 | qualitative | 21 | Supports | Interviews revealed themes including perceived therapeutic benefits of MDMA-AP, importance of expectation management, comprehensive screening, flexible protocols, and duty of care in establishing strong therapeutic alliance. |
This position paper discusses SSRIs, psilocybin, and MDMA as therapeutic modalities for PTSD, emphasizing the need for better understanding of their neurobiological mechanisms and intellectual property considerations.
review
This living meta-analytic dataset includes MDMA therapy vs. control comparisons for PTSD, providing effect sizes at post-test and long-term follow-ups, with data independently extracted and risk of bias assessed.
meta-analytic dataset
This review proposes a synergistic model where MDMA-assisted therapy works through both neurobiological mechanisms (fear extinction, neuroplasticity) and relational mechanisms (enhanced therapeutic alliance), creating a 'window of emotional safety'.
review
At-home ketamine-assisted therapy was associated with a 44.6% reduction in PTSD symptoms (Cohen's d=1.44), with 79.7% clinical response and 60.7% remission rates after six sessions.
retrospective analysis Sample size: 374
Lifetime MDMA use was not significantly associated with meaning in life overall, but a significant interaction showed that MDMA use was associated with higher meaning in life among individuals with a history of childhood trauma.
observational Sample size: 807
Firefighters reported feeling stuck, stigma around PTSD and ketamine, the need for self-advocacy, and substantial financial/logistical barriers to accessing ketamine-assisted therapy.
qualitative Sample size: 6
Interviews revealed themes including perceived therapeutic benefits of MDMA-AP, importance of expectation management, comprehensive screening, flexible protocols, and duty of care in establishing strong therapeutic alliance.
qualitative Sample size: 21
Points of agreement
- MDMA-assisted therapy is viewed as a promising treatment for PTSD, especially for those unresponsive to conventional therapies.
- Both MDMA and ketamine-assisted therapies show potential for large symptom reductions in PTSD.
- Qualitative studies highlight the importance of therapeutic alliance and comprehensive care in psychedelic-assisted therapies.
Conflicts
- The retrospective analysis on ketamine shows very large effect sizes, but these are from an uncontrolled design, while the MDMA evidence is from reviews and a meta-analytic dataset with more controlled comparisons.
- The observational study on naturalistic MDMA use found no overall association with meaning in life, only an interaction with childhood trauma, which contrasts with the positive findings from clinical contexts.
Gaps
- Long-term durability of treatment effects for both MDMA and ketamine-assisted therapies is not well-established in the February 2026 literature.
- There is a lack of large, double-blind, randomized controlled trials directly comparing these interventions to standard care or placebo.
- Real-world effectiveness and accessibility barriers, especially financial and logistical, are understudied.
- Mechanistic understanding of how these therapies work at molecular and neural circuit levels remains limited.